Börsipäev 20. september
Log in or create an account to leave a comment
-
Teisipäeval ületas põhinimekirja käive 1 miljoni euro piiri 376 tehinguga, millest Tallinna börsi käive moodustas 244 tehinguga 789 tuhat eurot ja Vilniuse börsi käive 89 tehinguga 163 tuhat eurot. Indeksitest sulgusid Tallinn (-0.17%) ja Riia (-0.14%) miinuspoolel ja Vilnius (+0.29%) plusspoolel.
Enimkaubeldud aktsia oli Tallink Grupp (-1.87%) käibega 309 tuhat eurot ja tehingute arv oli 86 (üks plokktehing EUR 1.050 x 30176). Olympic Entertainment Group (+1.09%) aktsiaga tehti 52 tehingut kogumahus 266 tuhat eurot. Järgnes Šiaulių bankas (+0.18%) 38 tehingu ja käibga 125 tuhat eurot.
Suurimad tõusjad olid Baltika (+3.20%, käive EUR 500), SAF Tehnika (+2.40%, käive EUR 3k), Nordecon (+1.54%, käive EUR 3k). Enim langesid PRFoods (-4.11%, käive EUR 25k), Lietuvos energijos gamyba (-3.16%, käive EUR 2k), Olainfarm (-1.94%, käive EUR 32k). -
Ühendriikide aktsiaturu indeksid venitasid väikeste liikumistega välja uued rekordid (S&P 500 +0,1%), kui investorid näitasid FOMC tänase otsuse eel üles huvi finantssektori vastu ning uudis Sprinti ja T-Mobile US-i võimalikust ühinemisest lennutas telekommunikatsioonisektori indeksi 2,3% kõrgemale. Euroopas alustasid aktsiaturud sessiooni madalamal, kuid päeva lõpuks suudeti kaotused pöörata marginaalseks plussiks.
USA alustatud elamuehituste arv vähenes augustis annualiseeritult -0,8% 1,18 miljonini, mis kujunes ootuspäraseks tänu sellele, et eelnevate kuude näitajaid revideeriti kõrgemaks. Regionaalsest statistikast oli näha, et augusti nõrkuse võib lükata suuresti orkaan Harvey arvele ning tõenäoliselt on orkaan Irma tõttu moonutatud ka septembri aktiivsus. Väljastatud ehituslubade arv kasvas annualiseeritult 5,7% 1,3 miljonini, ületades konsensuse 1,22 miljoni suurust ootust, ent kogu kasv tulenes korterelamute arvelt ning tõenäoliselt on sedagi statistikat lähikuudel keeruline tõlgendada.
Tänase istungi lõppedes peaks FOMC panema paika kuu, millal alustatakse varade ostuprogrammiga 4,47 triljoni dollarini kasvanud bilansi vähendamist. Kuna turuosalised juba arvestavad oktoobriga, võidakse rohkem tähelepanu pöörata värsketele majandusprognoosidele ning sellele, kas bilansi vähendamine võib kuidagi mõjutada intressimäära ootusi tulevikus.
11.30 Suurbritannia jaemüük (august)
17.00 USA olemasolevate majade müük (august)
21.00 USA FOMC istung -
Suurbirtannia jaemüük kasvas augustis autosid ja kütust arvestamata MoM 1,0% vs oodatud 0,1% (YoY 2,8% vs prog 1,4%), toites sellega naela edasist tugevnemist
-
OECD teeb marginaalsed muutused oma majanduskasvu ootustes
OECD sees 2017 World Growth Of 3.5% (Unchanged From June Estimates), 3.7% In 2018 (+0.1% Point)
OECD sees US Growth Of 2.1% In 2017, 2.4% In 2018 (Both Unchanged)
OECD sees Euro Zone Growth Of 2.1% In 2017 (+0.3), 1.9% In 2018 (+0.1)
OECD sees Japanese Growth Of 1.6% In 2017 (+0.2), 1.2% In 2018 (+0.2)
OECD sees UK Growth Of 1.6% In 2017, 1.0% In 2018 (Both Unchanged)
OECD sees Chinese Growth Of 6.8% In 2017 (+0.2), 6.6% In 2018 (+0.2) -
Gapping up
In reaction to strong earnings/guidance:
KOOL +9.1%, CPRT +4.5%
Other news:
WAC +61.5% (entered into a commitment letter with Barclays who has agreed to increase financing available)
ALNY +20.7% (Alnylam Pharma and Sanofi (SNY) announce that the APOLLO Phase 3 study of patisiran met its primary efficacy endpoint and all secondary endpoints)
GEMP +15% (plans to advance its product candidate gemcabene into Phase 3 development in 2018 and is preparing for end of Phase 2 meeting w/ the FDA and EMA in early 2018 )
HTGM +14.7% (USPTO has issued two U.S. Patents covering HTG's technology and applications of its technology)
KPTI +13.1% (reports 'a successful outcome from the Phase 2 portion of the SEAL study)
IBIO +9.1% (provides update on recent patents; received patent entitled 'system for expression of genes in plants')
MBII +4.6% (ÉLÉPHANT VERT will develop and market two of MBI's products in Morocco, Tunisia and Algeria )
AVEO +3.9% (announces that EUSA Pharma has opted into the Phase 1/2 TiNivo study, triggers $2 mln R&D payment to AVEO)
MZOR +2.7% (receives CE Mark in EU approval for its Mazor X Surgical Assurance Platform)
AUPH +1.6% (will host an R&D Day on October 20 at 8:00am ET)
S +1.5% (continued strength)
STON +1.4% (obtained New York Stock Exchange listing extension and 2016 10-K is now available)
CX +1.3% ( offers to purchase for cash any and all of CEMEX Finance LLC's outstanding 9.375% Senior Secured Notes due 2022)
RESI +1.1% (provides update on impact of Hurricane Irma; inspections so far indicate limited damage relative to co's overall portfolio )
Analyst comments:
CBAY +5.4% (initiated with a Overweight at Cantor Fitzgerald)
EVH +1.3% (initiated with a Overweight at KeyBanc Capital Mkts)
AAL +1.1% (upgraded to Outperform from Mkt Perform at Raymond James)
ATVI +1.1% (initiated with a Buy at Buckingham Research)
EA +1% (initiated with a Buy at Buckingham Research)
PFE +0.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
Gapping down
In reaction to disappointing earnings/guidance:
BBBY -14.7%, GIS -4.7%, ADBE -2.4%, DEO -2.1%, (guidance at AGM), FDX -1.2%, STLD -0.8%
M&A news:
WDC -3.5% (report that Toshiba (TOSBF) may select Bain Capital/Apple (AAPL) bid for chip unit sale)
Other news:
IONS -8.6% (following positve Phase 3 hereditary ATTR amyloidosis data from competitor Alnylam)
NBRV -5.3% (prices offering of 9,411,765 ordinary shares at $8.50 per share)
BBU -4.3% (to issue 6,670,000 limited partnership units on a bought deal basis at $30.00/unit for gross proceeds of approximately $200 million)
MXWL -3% (amends/restates Viex agreement; proposes offering of $50 mln convertible senior notes due 2022 in a private offering)
WSM -2.3% (following BBBY results)
MDXG -0.8% (MiMedx Group to host call on September 21 at 10:30am ET to update progress on strategic initiatives and respond to topics requested by shareholders)
Analyst comments:
JNJ -1.5% (downgraded to Sell from Neutral at Goldman)
AGN -1.4% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
MMM -1.2% (downgraded to Underweight from Neutral at JP Morgan)
GIII -0.9% (initiated with Underweight ratings at Barclays)
Briefing.com -
